Bl1107

Phase 2

BBausch & Lomb Incorporated

Bl1107 is one of 2 therapeutic programs targeting Dry Eye Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Dry Eye DiseaseNot yet recruiting

Dry Eye DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Dry Eye Disease

#DrugCompanyPhaseTrials

Xiidra

BBausch Health Americas, Inc.

Approved

2 2

Bl1107

BBausch & Lomb Incorporated

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Dry Eye Disease

NCT07778888

Clinical

Trials by Indication[1]

Dry Eye Disease1 trial

Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease

Not yet recruiting·BBausch & Lomb Incorporated·Phase 2·NCT07778888·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bl1107. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bl1107. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bausch & Lomb Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBausch & Lomb Incorporated

Bl1107

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Dry Eye Disease1 trial

References

Drug Info

Quick Facts

Related News